Disclosures for "Galectin-3 as a Novel Inflammatory Biomarker in Acute Inflammatory Polyradiculopathies: A Pilot Study"
-
Dr. siconolfi has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Alnylam. Marco Luigetti has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for AstraZeneca.